Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $10.8 million.

  • Burning Rock Biotech's Accumulated Expenses fell 1934.98% to $10.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year decrease of 1934.98%. This contributed to the annual value of $12.3 million for FY2024, which is 1703.65% down from last year.
  • According to the latest figures from Q3 2025, Burning Rock Biotech's Accumulated Expenses is $10.8 million, which was down 1934.98% from $10.5 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Accumulated Expenses ranged from a high of $90.0 million in Q4 2021 and a low of -$4.4 million during Q2 2022
  • In the last 5 years, Burning Rock Biotech's Accumulated Expenses had a median value of $12.6 million in 2024 and averaged $17.3 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Accumulated Expenses surged by 60184.09% in 2021, and later plummeted by 13560.21% in 2022.
  • Burning Rock Biotech's Accumulated Expenses (Quarter) stood at $90.0 million in 2021, then tumbled by 71.99% to $25.2 million in 2022, then plummeted by 41.36% to $14.8 million in 2023, then dropped by 17.04% to $12.3 million in 2024, then fell by 11.79% to $10.8 million in 2025.
  • Its Accumulated Expenses stands at $10.8 million for Q3 2025, versus $10.5 million for Q2 2025 and $10.5 million for Q1 2025.